Refractory Ulcerative Colitis Improved by Scheduled Combination Therapy of Vedolizumab and Granulocyte and Monocyte Adsorptive Apheresis

Granulocyte and monocyte adsorptive apheresis (GMA) is occasionally introduced as an alternative combination therapy after loss of response to biologics in ulcerative colitis (UC) patients. However, there have been no reports of the concomitant use of vedolizumab (VDZ) and GMA for the initial induct...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamura, Masanao, Yamamura, Takeshi, Maeda, Keiko, Sawada, Tsunaki, Mizutani, Yasuyuki, Ishikawa, Eri, Ohashi, Ayako, Kajikawa, Go, Furukawa, Kazuhiro, Ohno, Eizaburo, Honda, Takashi, Kawashima, Hiroki, Ishigami, Masatoshi, Fujishiro, Mitsuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7759717/
https://www.ncbi.nlm.nih.gov/pubmed/32727993
http://dx.doi.org/10.2169/internalmedicine.5302-20
_version_ 1783627166760566784
author Nakamura, Masanao
Yamamura, Takeshi
Maeda, Keiko
Sawada, Tsunaki
Mizutani, Yasuyuki
Ishikawa, Eri
Ohashi, Ayako
Kajikawa, Go
Furukawa, Kazuhiro
Ohno, Eizaburo
Honda, Takashi
Kawashima, Hiroki
Ishigami, Masatoshi
Fujishiro, Mitsuhiro
author_facet Nakamura, Masanao
Yamamura, Takeshi
Maeda, Keiko
Sawada, Tsunaki
Mizutani, Yasuyuki
Ishikawa, Eri
Ohashi, Ayako
Kajikawa, Go
Furukawa, Kazuhiro
Ohno, Eizaburo
Honda, Takashi
Kawashima, Hiroki
Ishigami, Masatoshi
Fujishiro, Mitsuhiro
author_sort Nakamura, Masanao
collection PubMed
description Granulocyte and monocyte adsorptive apheresis (GMA) is occasionally introduced as an alternative combination therapy after loss of response to biologics in ulcerative colitis (UC) patients. However, there have been no reports of the concomitant use of vedolizumab (VDZ) and GMA for the initial induction of UC. A 20-year-old man with refractory UC was admitted for recrudescence. VDZ monotherapy had previously been introduced but was ineffective. Therefore, he received scheduled combination of VDZ and GMA and achieved clinical remission. The combination of two different approaches to inhibit the migration of leukocytes into the inflamed tissue led to satisfactory clinical outcomes.
format Online
Article
Text
id pubmed-7759717
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-77597172020-12-31 Refractory Ulcerative Colitis Improved by Scheduled Combination Therapy of Vedolizumab and Granulocyte and Monocyte Adsorptive Apheresis Nakamura, Masanao Yamamura, Takeshi Maeda, Keiko Sawada, Tsunaki Mizutani, Yasuyuki Ishikawa, Eri Ohashi, Ayako Kajikawa, Go Furukawa, Kazuhiro Ohno, Eizaburo Honda, Takashi Kawashima, Hiroki Ishigami, Masatoshi Fujishiro, Mitsuhiro Intern Med Case Report Granulocyte and monocyte adsorptive apheresis (GMA) is occasionally introduced as an alternative combination therapy after loss of response to biologics in ulcerative colitis (UC) patients. However, there have been no reports of the concomitant use of vedolizumab (VDZ) and GMA for the initial induction of UC. A 20-year-old man with refractory UC was admitted for recrudescence. VDZ monotherapy had previously been introduced but was ineffective. Therefore, he received scheduled combination of VDZ and GMA and achieved clinical remission. The combination of two different approaches to inhibit the migration of leukocytes into the inflamed tissue led to satisfactory clinical outcomes. The Japanese Society of Internal Medicine 2020-07-28 2020-12-01 /pmc/articles/PMC7759717/ /pubmed/32727993 http://dx.doi.org/10.2169/internalmedicine.5302-20 Text en Copyright © 2020 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Nakamura, Masanao
Yamamura, Takeshi
Maeda, Keiko
Sawada, Tsunaki
Mizutani, Yasuyuki
Ishikawa, Eri
Ohashi, Ayako
Kajikawa, Go
Furukawa, Kazuhiro
Ohno, Eizaburo
Honda, Takashi
Kawashima, Hiroki
Ishigami, Masatoshi
Fujishiro, Mitsuhiro
Refractory Ulcerative Colitis Improved by Scheduled Combination Therapy of Vedolizumab and Granulocyte and Monocyte Adsorptive Apheresis
title Refractory Ulcerative Colitis Improved by Scheduled Combination Therapy of Vedolizumab and Granulocyte and Monocyte Adsorptive Apheresis
title_full Refractory Ulcerative Colitis Improved by Scheduled Combination Therapy of Vedolizumab and Granulocyte and Monocyte Adsorptive Apheresis
title_fullStr Refractory Ulcerative Colitis Improved by Scheduled Combination Therapy of Vedolizumab and Granulocyte and Monocyte Adsorptive Apheresis
title_full_unstemmed Refractory Ulcerative Colitis Improved by Scheduled Combination Therapy of Vedolizumab and Granulocyte and Monocyte Adsorptive Apheresis
title_short Refractory Ulcerative Colitis Improved by Scheduled Combination Therapy of Vedolizumab and Granulocyte and Monocyte Adsorptive Apheresis
title_sort refractory ulcerative colitis improved by scheduled combination therapy of vedolizumab and granulocyte and monocyte adsorptive apheresis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7759717/
https://www.ncbi.nlm.nih.gov/pubmed/32727993
http://dx.doi.org/10.2169/internalmedicine.5302-20
work_keys_str_mv AT nakamuramasanao refractoryulcerativecolitisimprovedbyscheduledcombinationtherapyofvedolizumabandgranulocyteandmonocyteadsorptiveapheresis
AT yamamuratakeshi refractoryulcerativecolitisimprovedbyscheduledcombinationtherapyofvedolizumabandgranulocyteandmonocyteadsorptiveapheresis
AT maedakeiko refractoryulcerativecolitisimprovedbyscheduledcombinationtherapyofvedolizumabandgranulocyteandmonocyteadsorptiveapheresis
AT sawadatsunaki refractoryulcerativecolitisimprovedbyscheduledcombinationtherapyofvedolizumabandgranulocyteandmonocyteadsorptiveapheresis
AT mizutaniyasuyuki refractoryulcerativecolitisimprovedbyscheduledcombinationtherapyofvedolizumabandgranulocyteandmonocyteadsorptiveapheresis
AT ishikawaeri refractoryulcerativecolitisimprovedbyscheduledcombinationtherapyofvedolizumabandgranulocyteandmonocyteadsorptiveapheresis
AT ohashiayako refractoryulcerativecolitisimprovedbyscheduledcombinationtherapyofvedolizumabandgranulocyteandmonocyteadsorptiveapheresis
AT kajikawago refractoryulcerativecolitisimprovedbyscheduledcombinationtherapyofvedolizumabandgranulocyteandmonocyteadsorptiveapheresis
AT furukawakazuhiro refractoryulcerativecolitisimprovedbyscheduledcombinationtherapyofvedolizumabandgranulocyteandmonocyteadsorptiveapheresis
AT ohnoeizaburo refractoryulcerativecolitisimprovedbyscheduledcombinationtherapyofvedolizumabandgranulocyteandmonocyteadsorptiveapheresis
AT hondatakashi refractoryulcerativecolitisimprovedbyscheduledcombinationtherapyofvedolizumabandgranulocyteandmonocyteadsorptiveapheresis
AT kawashimahiroki refractoryulcerativecolitisimprovedbyscheduledcombinationtherapyofvedolizumabandgranulocyteandmonocyteadsorptiveapheresis
AT ishigamimasatoshi refractoryulcerativecolitisimprovedbyscheduledcombinationtherapyofvedolizumabandgranulocyteandmonocyteadsorptiveapheresis
AT fujishiromitsuhiro refractoryulcerativecolitisimprovedbyscheduledcombinationtherapyofvedolizumabandgranulocyteandmonocyteadsorptiveapheresis

Ejemplares similares